| Revenue growth | Portfolio revenue ~€62M for FY25. |
|---|---|
| Margins | Strong expansion potential via API integration and cost optimization. |
| Demand visibility | Sustained demand driven by global TB burden and AMR focus. |
| Management confidence | High: Strategic milestone toward high-margin fermentation platform. |
Growth
Acquired portfolio generated ~€62M revenue in FY25; expected to be EPS accretive with healthy gross margins.
Outlook
Targeting margin expansion via API forward integration; deal funded by debt and equity; asset-light model with no capex.
Risks
Subject to antitrust/FDI approvals; risks include global supply chain stability and integration of 55+ country markets.
Earnings Call filed with BSE, NSE: GUJTHEM. Summary written with AI assistance from the document.
Gujarat Themis Biosyn Ltd: key numbers
- Share price
- ₹397.55
- Market cap
- ₹5,174 Cr
- Revenue (annual)
- ₹165.8 Cr
- Net profit (annual)
- ₹46.68 Cr
- P/E (TTM)
- 106.3×Sector 49.7×
- Promoter holding
- 59.33%-11.53% QoQ
- FII holding
- 4.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Themis Biosyn Ltd
All →Gujarat Themis Biosyn Annual General Meeting
Gujarat Themis Biosyn issued a corrigendum to its 45th AGM notice, updating the preferential issue resolution regarding share price, issue size, and allottee details.
Gujarat Themis Biosyn Acquisition Worth ₹1,300 Cr
Gujarat Themis Biosyn Limited acquired MicroBiopharm Japan Co. Ltd. for approximately ₹1,300 Crore. This acquisition expands its pharmaceutical CDMO capabilities.
- Value
- ₹1,300 Cr
Gujarat Themis Biosyn Dividend
Gujarat Themis Biosyn Limited has fixed September 23, 2026, as the record date for determining member entitlement for the final dividend for FY 2025-26.
Gujarat Themis Biosyn Acquisition Worth ₹1,333 Cr
GTBL completed 100% acquisition of MBJ Japan for JPY 21.5 billion (~₹1,333 Cr). The deal adds three GMP plants and precision fermentation capabilities.
- Value
- ₹1,333 Cr
- GMP-compliant manufacturing plants
- 3 plants
Gujarat Themis Biosyn Debt & Borrowing
Gujarat Themis Biosyn Limited announced the allotment of non-convertible debt securities. The filing serves as a regulatory disclosure regarding the issuance of these instruments.
Gujarat Themis Biosyn Other Announcement
Gujarat Themis Biosyn Ltd has submitted its quarterly shareholding pattern. This filing is a routine disclosure mandated by SEBI regulations.